MGRC Stock Overview
An investment holding company, provides genetics, genomics, immunotherapy, and biopharmaceutical services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Malaysian Genomics Resource Centre Berhad Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RM 0.33 |
| 52 Week High | RM 0.47 |
| 52 Week Low | RM 0.27 |
| Beta | 1.03 |
| 11 Month Change | -2.94% |
| 3 Month Change | -13.16% |
| 1 Year Change | -29.03% |
| 33 Year Change | -86.69% |
| 5 Year Change | 4.76% |
| Change since IPO | -64.89% |
Recent News & Updates
Recent updates
Is Now An Opportune Moment To Examine Malaysian Genomics Resource Centre Berhad (KLSE:MGRC)?
Mar 02
We Think Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Can Afford To Drive Business Growth
Feb 15Companies Like Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Are In A Position To Invest In Growth
Nov 02Shareholder Returns
| MGRC | MY Life Sciences | MY Market | |
|---|---|---|---|
| 7D | 0% | -2.8% | 0.09% |
| 1Y | -29.0% | -14.0% | 9.5% |
Return vs Industry: MGRC underperformed the MY Life Sciences industry which returned -14% over the past year.
Return vs Market: MGRC underperformed the MY Market which returned 9.5% over the past year.
Price Volatility
| MGRC volatility | |
|---|---|
| MGRC Average Weekly Movement | 5.4% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in MY Market | 10.4% |
| 10% least volatile stocks in MY Market | 2.5% |
Stable Share Price: MGRC has not had significant price volatility in the past 3 months compared to the MY market.
Volatility Over Time: MGRC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | n/a | www.mgrc.com.my |
Malaysian Genomics Resource Centre Berhad, an investment holding company, provides genetics, genomics, immunotherapy, and biopharmaceutical services worldwide. It offers genome sequencing of various human, animal, plant, and microbes and other living organisms, such as whole genome and transcriptome sequencing, and metagenomics and metatranscriptomics services. The company also provides genome analysis services comprising bioinformatics services, including reads quality analysis, whole genome assembly, variation analysis of genomes, gene annotation, and exome and transcriptome analysis, as well as other analytical pipelines for processing ChIP-Seq data, annotating and analyzing microRNAs, and analyzing mutations; trait analysis services to screen multiple samples of previously identified genetic markers within plant and animal genomes; and trio sequencing services that provide a detailed view of an individual’s DNA.
Malaysian Genomics Resource Centre Berhad Fundamentals Summary
| MGRC fundamental statistics | |
|---|---|
| Market cap | RM 45.28m |
| Earnings (TTM) | -RM 7.90m |
| Revenue (TTM) | RM 9.74m |
4.6x
P/S Ratio-5.7x
P/E RatioIs MGRC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGRC income statement (TTM) | |
|---|---|
| Revenue | RM 9.74m |
| Cost of Revenue | RM 4.10m |
| Gross Profit | RM 5.65m |
| Other Expenses | RM 13.54m |
| Earnings | -RM 7.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.058 |
| Gross Margin | 57.96% |
| Net Profit Margin | -81.06% |
| Debt/Equity Ratio | 0% |
How did MGRC perform over the long term?
See historical performance and comparison